Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product

Leeuw, de Karina; Kusumanto, Yoka H.; Smit, Andries J.; Oomen, P. H. N.; Hoeven, van der Johannes; Mulder, Nanno; Hospers, Geke A.P.

doi:10.1111/j.1464-5491.2008.02557.x

Cited by 4 publications

(1 citation statement)

References 21 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An improvement in neuropathic symptoms was observed but without an effect on nerve conduction or quantitative sensory examination [Ropper et al 2009]. Although an increased incidence of side effects was observed this was not characterized by increased oedema or haemorrhage, as might have been predicted recently with the demonstration of increased capillary leakage following VEGF treatment [de Leeuw et al 2008]. Thus, the demonstration of a clinical benefit for diabetic neuropathy after VEGF treatment is at best, limited.…”

Section: Vascular Endothelial Growth Factormentioning

confidence: 84%

Review: Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy

Tavakoli

Asghar

Alam

et al. 2010

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the 'placebo effect' and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.

show abstract

Section: Vascular Endothelial Growth Factormentioning

confidence: 84%

Review: Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy

Tavakoli

Asghar

Alam

et al. 2010

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

Growth factors for angiogenesis in peripheral arterial disease

Gorenoi

Brehm

Koch

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The results of this review do not support the use of therapy with the growth factors FGF, HGF or VEGF in people with PAD of the lower extremities to prevent death or major limb amputation or to improve walking ability. However, the use of these growth factors may improve haemodynamic measures and decrease the rate of any limb amputations (probably due to preventing minor amputations) with an uncertain effect on adverse events; an improvement of ulceration and rest pain is very uncertain. New trials at low risk of bias are needed to generate evidence with more certainty.

show abstract

Gene therapy for peripheral arterial disease

Forster

Liew

Bhattacharya

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product

Abstract: No increase in capillary leakage in DM-CLI was found, probably because an increased capillary filtration coefficient is counterbalanced by a marked fall in perfusion pressures. Increased capillary leakage may be one explanation for oedema formation after VEGF treatment.

Cited by 4 publications

References 21 publications

Review: Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy

Review: Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy

Growth factors for angiogenesis in peripheral arterial disease

Gene therapy for peripheral arterial disease

Contact Info

Product

Resources

About